FMP

FMP

Enter

FSTX - F-star Therapeu...

photo-url-https://images.financialmodelingprep.com/symbol/FSTX.png

F-star Therapeutics, Inc.

FSTX

NASDAQ

Inactive Equity

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

7.12 USD

0 (0%)

Historical Prices

From:

To:

page loading card

About

ceo

Dr. Eliot Richard Forster M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-s...

CIK

0001566373

ISIN

US30315R1077

CUSIP

30315R107

Address

Eddeva B920

Phone

44 1223 497400

Country

GB

Employee

84

IPO Date

May 6, 2016

Financial Statement

-20M-10M010M20M2021 Q32021 Q42022 Q12022 Q22022 Q3RevenueNet Income

Earnings

-1.2-0.9-0.6-0.300.30.62021 Q22021 Q32021 Q42022 Q12022 Q22022 Q32022 Q42023 Q1EPS Consensus

FSTX Financial Summary

CIK

0001566373

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

30315R107

ISIN

US30315R1077

Country

GB

Price

7.12

Beta

-0.35

Volume Avg.

747.28k

Market Cap

156.51M

Shares

-

52-Week

2.07-7.12

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.89

P/B

-

Website

https://www.f-star.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest FSTX News

Seeking Alpha

Jan 28, 2023

F-star's Delayed Acquisition Presents A Risky Opportunity

FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.

Seeking Alpha

Jul 29, 2022

F-star Therapeutics: A Merger Arbitrage Opportunity Expected...

F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.

Zacks Investment Research

Jul 15, 2022

New Strong Buy Stocks for July 15th

GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.

Zacks Investment Research

Jun 24, 2022

F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

Benzinga

Jun 23, 2022

F-star Therapeutics Shares Are Rallying Today - Read Why

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share.  The proposed acquisition values F-star at approximately $161 million.

Zacks Investment Research

May 10, 2022

Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenu...

Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

May 3, 2022

Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Es...

Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha

Mar 14, 2022

F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 202...

F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep